Malignancy After Heart Transplantation

Journal of the Chinese Medical Association

Volumn 72, Issue 11, 2009, Pages 588-593

  Chen, Po Lin ^a   Chang, Hsiao Huang ^a   Chen, I Ming ^a   Lai, Shiau Ting ^a   Shih, Chun Che ^a   Weng, Zen Chung ^a   Hsieh, Yuan Chen ^b   Yang, An Hang ^b  

^a Division of Cardiovascular Surgery   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

heart transplantation; malignancy; post transplant lymphoproliferative disorder

Indexed keywords

ADULT; AGED; ARTICLE; CHEEK; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EARLY DIAGNOSIS; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE ORGAN FAILURE; POSTOPERATIVE PERIOD; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PROSTATE CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; CHILD; CYCLOSPORINE; HEART TRANSPLANTATION; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SKIN NEOPLASMS;

EID: 74249087488     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70434-4     Document Type: Article

References (25)

1. Aurora P., Edwards L.B., Christie J., Dobbels F., Kirk R., Kucheryavaya A.Y., Rahmel A.O., et al. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric lung and heart/lung transplantation report-2008. J Heart Lung Transplant 27 (2008) 978-983
2. Penn I., and Starzl T.E. A summary of the status of de novo cancer in transplant recipients. Transplant Proc 4 (1972) 719-732
3. El-Hamamsy I., Stevens L.M., Carrier M., Pelletier G., White M., Tremblay F., and Perrault L.P. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transpl Int 18 (2005) 1280-1285
4. O'Neill J.O., Edwards L.B., and Taylor D.O. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25 (2006) 1186-1191
5. Roithmaier S., Haydon A.M., Loi S., Esmore D., Griffiths A., Bergin P., Williams T.J., et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 26 (2007) 845-849
6. Crespo-Leiro M.G., Alonso-Pulpon L., Vazquez de Prada J.A., Almenar L., Arizon J.M., Brossa V., Delgado J.F., et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant 8 (2008) 1031-1039
7. Hsu R.B., Chen R.J., Chou N.K., Ko W.J., Wang S.S., and Chu S.H. Low incidence of malignancy after transplantation in Chinese heart allograft recipients. Transpl Int 18 (2005) 283-288
8. Hartevelt M.M., Bavinck J.N., Kootte A.M., Vermeer B.J., and Vanden-broucke J.P. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49 (1990) 506-509
9. Bouwes Bavinck J.N., Hardie D.R., Green A., Cutmore S., MacNaught A., O'Sullivan B., Siskind V., et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 61 (1996) 715-721
10. Walker R.C., Paya C.V., Marshall W.F., Strickler J.G., Wiesner R.H., Velosa J.A., Habermann T.M., et al. Pre-transplantation seronegative Epstein-Barr virus status is the primary risk factor for post-transplant lymphoproliferative disorder in adult heart, lung, and other solid organ transplantation. J Heart Lung Transplant 12 (1995) 214-221
11. Nelson B.P., Nalesnik M.A., Bahler D.W., Locker J., Fung J.J., and Swerdlow S.H. Epstein-Barr virus-negative post-transplant lym-phoproliferative disorders: a distinct entity?. Am J Surg Pathol 24 (2000) 375-385
12. Cox K.L., Lawrence-Miyasaki L.S., Garcia-Kennedy R., Lennette E.T., Martinez O.M., Krams S.M., Berquist W.E., et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59 (1995) 524-529
13. Opelz G., and Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 222-230
14. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., O'Sullivan E.J., Johnson M.R., Heroux A.L., Dizikes G.J., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323 (1990) 1723-1728
15. Hoshida Y., Tsukuma H., Yasunaga Y., Xu N., Fujita M.Q., Satoh T., Ichikawa Y., et al. Cancer risk after renal transplantation in Japan. Int J Cancer 71 (1997) 517-520
16. Dotti G., Fiocchi R., Motta T., Gamba A., Gotti E., Gridelli B., Borleri G., et al. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 69 (2000) 827-833
17. Hayashi R.J., Kraus M.D., Patel A.L., Canter C., Cohen A.H., Hmiel P., Howard T., et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 23 (2001) 14-18
18. Rinaldi M., Pellegrini C., D'Armini A.M., Aiello M., Negri M., Arbustini E., Ippoliti G., et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 19 (2001) 696-701
19. Penn I. Cancers in cyclosporine-treated versus azathioprine-treated patients. Transplant Proc 28 (1996) 876-878
20. Jensen P., Hansen S., Moller B., Leivestad T., Pfeffer P., Geiran O., Fauchald P., et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40 (1999) 177-186
21. Gruber S.A., Gillingham K., Sothern R.B., Stephanian E., Matas A.J., and Dunn D.L. De novo cancer in cyclosporine-treated and non cyclosporine-treated adult primary renal allograft recipients. Clin Transpl 8 (1994) 388-395
22. Hiesse C., Rieu P., Kriaa F., Larue J.R., Goupy C., Neyrat N., and Charpentier B. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 29 (1997) 240-242
23. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530-534
24. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Safety 23 (2000) 101-113
25. Wiesner R.H. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 66 (1998) 493-499